These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31902709)

  • 1. Corrigendum to "Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core" [Bioorg. Med. Chem. Lett. 26 (2016) 5399-5402].
    Han M; Wang C; Ji Y; Song Z; Xing L; Su Y; Wang X; Zhang A; Ai J; Geng M
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126931. PubMed ID: 31902709
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core.
    Han M; Wang C; Ji Y; Song Z; Xing L; Su Y; Wang X; Zhang A; Ai J; Geng M
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5399-5402. PubMed ID: 27769623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.
    Song Z; Xia Z; Ji Y; Xing L; Gao Y; Ai J; Geng M; Zhang A
    Eur J Med Chem; 2016 Aug; 118():244-9. PubMed ID: 27131066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to "Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury" [Bioorg. Med. Chem. Lett. 29(8) (2019) 995-1000].
    Goncalves MB; Clarke E; Jarvis CI; Kalindjian SB; Pitcher T; Grist J; Hobbs C; Carlstedt T; Jack J; Brown JT; Mills M; Mumford P; Borthwick AD; Corcoran JPT
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2440-2441. PubMed ID: 31208764
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors" [Bioorg. Med. Chem. Lett. 24 (2014) 5093-5097].
    Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3205. PubMed ID: 28551102
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors" [Bioorg. Med. Chem. Lett. 60 (2022) 128549].
    Ma B; Metrick CM; Gu C; Hoemberger M; Bajrami B; Bame E; Huang J; Mingueneau M; Murugan P; Nevalainen M; Santoro JC; Tang H; Wang T; Hopkins BT
    Bioorg Med Chem Lett; 2022 Sep; 72():128856. PubMed ID: 35728998
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "A selective delta opioid receptor antagonist based on a stilbene core" [Bioorg. Med. Chem. Lett. 25 (2015) 5532-5535].
    Hartung AM; Navarro HA; Wiemer DF; Neighbors JD
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1645. PubMed ID: 28750745
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
    Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
    Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum to "Structure guided development of potent piperazine-derived hydroxamic acid inhibitors targeting falcilysin" [Bioorg. Med. Chem. Lett. 32 (2021) 127683].
    Kahlon G; Lira R; Masvlov N; Pompa E; Brar N; Eagon S; Anderson MO; Andaya A; Chance JP; Fejzic H; Keniston A; Huynh N; Celis N; Vidal B; Trieu N; Rodriguez P; Mallari JP
    Bioorg Med Chem Lett; 2021 Apr; 37():127836. PubMed ID: 33588181
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects" [Bioorg. Med. Chem. Lett. 26 (2016) 5724-5728].
    Lombardo M; Bender K; London C; Plotkin MA; Kirkland M; Mane J; Pachanski M; Geissler W; Cummings J; Habulihaz B; Akiyama TE; Di Salvo J; Madeira M; Pols J; Powles MA; Finley MF; Johnson E; Roussel T; Uebele VN; Crespo A; Leung D; Alleyne C; Trusca D; Lei Y; Howard AD; Ujjainwalla F; Tata JR; Sinz CJ
    Bioorg Med Chem Lett; 2017 Mar; 27(5):1333. PubMed ID: 28169160
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists" [Bioorg. Med. Chem. Lett. 24/5 (2014) 1426-1431].
    Wu TM; Wang DC; Xiang P; Zhang JN; Sang YX; Lin HJ; Chen J; Xie G; Song H; Zhao YL; Xie YM
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4558. PubMed ID: 27542309
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Discovery of highly selective κ-opioid receptor agonists: 10α-Hydroxy TRK-820 derivatives" [Bioorg Med Chem Lett 27(16) (2017) 3920-3924].
    Suzuki S; Sugawara Y; Tsuji R; Tanimura R; Kaneko C; Yuzawa N; Yagi M; Kawai K
    Bioorg Med Chem Lett; 2019 Feb; 29(3):515. PubMed ID: 30579796
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase" [Bioorg. Med. Chem. Lett. 29 (2019) 1918-1921].
    Kim SH; Johnson JA; Jiang J; Parkhurst B; Phillips M; Pi Z; Qiao JX; Tora G; Ye Chen A; Liu E; Yin X; Yang R; Zhao L; Taylor DS; Basso M; Behnia K; Onorato J; Chen XQ; Abell LM; Lu H; Locke G; Caporuscio C; Adam LP; Gordon D; Wexler RR; Finlay HJ
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2525. PubMed ID: 31353296
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Investigation of biaryl heterocycles as inhibitors of Wee1 kinase" [Bioorg. Med. Chem. Lett. 29 (2019) 1481-1486].
    Mastracchio A; Lai C; Torrent M; Bromberg K; Buchanan FG; Ferguson D; Bontcheva V; Johnson EF; Lasko L; Maag D; Shoemaker AR; Penning TD
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126895. PubMed ID: 31926787
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres" [Bioorg. Med. Chem. Lett. 24 (2014) 1062-1066].
    Sheffler DJ; Nedelcovych MT; Williams R; Turner SC; Duerk BB; Robbins MR; Jadhav SB; Niswender CM; Jones CK; Conn PJ; Nathan Daniels R; Lindsley CW
    Bioorg Med Chem Lett; 2017 May; 27(9):2079. PubMed ID: 28347668
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay" [Bioorg. Med. Chem. Lett. 25 (2015) 2505-2509].
    Arns S; Tan J; Sun S; Galey A; Zisman N; Ross F; Udechukwu J; Dercho S; Gusti V; Paquette J; Wennekes T; Webb M; Bourque E; Withers SG; Liggins R
    Bioorg Med Chem Lett; 2016 Jul; ():. PubMed ID: 27381085
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Challenges in the development of an M
    Tarr JC; Wood MR; Noetzel MJ; Melancon BJ; Lamsal A; Luscombe VB; Rodriguez AL; Byers FW; Chang S; Cho HP; Engers DW; Jones CK; Niswender CM; Wood MW; Brandon NJ; Duggan ME; Jeffrey Conn P; Bridges TM; Lindsley CW
    Bioorg Med Chem Lett; 2018 Sep; 28(17):3014. PubMed ID: 30076050
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Investigation of the structure activity relationship of flufenamic acid derivatives at the human TRESK channel K2P18.1" [Bioorg. Med. Chem. Lett. 26 (2016) 4919-4924].
    Monteillier A; Loucif A; Omoto K; Stevens EB; Lainez S; Saintot PP; Cao L; Pryde DC
    Bioorg Med Chem Lett; 2017 May; 27(9):2082. PubMed ID: 28320618
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
    Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
    Bioorg Med Chem; 2016 Sep; 24(18):4517. PubMed ID: 27544046
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
    Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
    Bioorg Med Chem; 2017 May; 25(10):2813. PubMed ID: 28366269
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.